We recently published a list of 12 Best Major Stocks to Buy According to Billionaires. In this article, we are going to take ...

Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) ...

On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks on Jim Cramer’s radar recently. On Monday’s episode of Mad Money, Jim Cramer ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its phase 3 Alzheimer's asset, remternetug, also binds to amyloid plaques. It is ...

The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP ...